Cargando…
Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis
BACKGROUND: It is still controversial in the current literature whether omalizumab is beneficial for children with asthma. Given that there is no high-quality meta-analysis to incorporate existing evidence, the purpose of this protocol is to design a systematic review and meta-analysis of the level...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183849/ https://www.ncbi.nlm.nih.gov/pubmed/34087872 http://dx.doi.org/10.1097/MD.0000000000026155 |
_version_ | 1783704458176233472 |
---|---|
author | Chen, Lu Chen, Yanping |
author_facet | Chen, Lu Chen, Yanping |
author_sort | Chen, Lu |
collection | PubMed |
description | BACKGROUND: It is still controversial in the current literature whether omalizumab is beneficial for children with asthma. Given that there is no high-quality meta-analysis to incorporate existing evidence, the purpose of this protocol is to design a systematic review and meta-analysis of the level I evidence to ascertain whether omalizumab is beneficial and safe for children with asthma. METHODS: The systematic literature review is structured to adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The following search terms will be used in PUBMED, Scopus, EMBASE, and Cochrane Library databases on June, 2021, as the search algorithm: (omalizumab) AND (asthma) AND (children). The primary outcome is the long-term safety and tolerability of omalizumab. The other outcomes include asthma control, quality of life, use of asthma controller medications, and spirometry measurements and emergency room visits due to asthma, and serum trough concentrations of omalizumab, free and total immunoglobulin E measured. Review Manager software (v 5.3; Cochrane Collaboration) will be used for the meta-analysis. RESULTS: The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings. REGISTRATION NUMBER: 10.17605/OSF.IO/G6N3P. |
format | Online Article Text |
id | pubmed-8183849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-81838492021-06-07 Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis Chen, Lu Chen, Yanping Medicine (Baltimore) 3800 BACKGROUND: It is still controversial in the current literature whether omalizumab is beneficial for children with asthma. Given that there is no high-quality meta-analysis to incorporate existing evidence, the purpose of this protocol is to design a systematic review and meta-analysis of the level I evidence to ascertain whether omalizumab is beneficial and safe for children with asthma. METHODS: The systematic literature review is structured to adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The following search terms will be used in PUBMED, Scopus, EMBASE, and Cochrane Library databases on June, 2021, as the search algorithm: (omalizumab) AND (asthma) AND (children). The primary outcome is the long-term safety and tolerability of omalizumab. The other outcomes include asthma control, quality of life, use of asthma controller medications, and spirometry measurements and emergency room visits due to asthma, and serum trough concentrations of omalizumab, free and total immunoglobulin E measured. Review Manager software (v 5.3; Cochrane Collaboration) will be used for the meta-analysis. RESULTS: The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings. REGISTRATION NUMBER: 10.17605/OSF.IO/G6N3P. Lippincott Williams & Wilkins 2021-06-04 /pmc/articles/PMC8183849/ /pubmed/34087872 http://dx.doi.org/10.1097/MD.0000000000026155 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 3800 Chen, Lu Chen, Yanping Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis |
title | Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis |
title_full | Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis |
title_fullStr | Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis |
title_full_unstemmed | Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis |
title_short | Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis |
title_sort | effects of omalizumab in children with asthma: a protocol for systematic review and meta-analysis |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183849/ https://www.ncbi.nlm.nih.gov/pubmed/34087872 http://dx.doi.org/10.1097/MD.0000000000026155 |
work_keys_str_mv | AT chenlu effectsofomalizumabinchildrenwithasthmaaprotocolforsystematicreviewandmetaanalysis AT chenyanping effectsofomalizumabinchildrenwithasthmaaprotocolforsystematicreviewandmetaanalysis |